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Abstract
Background: More than 85% of Rett syndrome (RTT) patients have heterozygous mutations in
the X-linked MECP2  gene which encodes methyl-CpG-binding protein 2, a transcriptional
repressor that binds methylated CpG sites. Because MECP2  is subject to X chromosome
inactivation (XCI), girls with RTT express either the wild type or mutant MECP2 in each of their
cells. To test the hypothesis that MECP2  mutations result in genome-wide transcriptional
deregulation and identify its target genes in a system that circumvents the functional mosaicism
resulting from XCI, we performed gene expression profiling of pure populations of untransformed
T-lymphocytes that express either a mutant or a wild-type allele.
Methods: Single T lymphocytes from a patient with a c.473C>T (p.T158M) mutation and one with
a c.1308-1309delTC mutation were subcloned and subjected to short term culture. Gene
expression profiles of wild-type and mutant clones were compared by oligonucleotide expression
microarray analysis.
Results: Expression profiling yielded 44 upregulated genes and 77 downregulated genes. We
compared this gene list with expression profiles of independent microarray experiments in cells
and tissues of RTT patients and mouse models with Mecp2  mutations. These comparisons
identified a candidate MeCP2 target gene, SPOCK1, downregulated in two independent microarray
experiments, but its expression was not altered by quantitative RT-PCR analysis on brain tissues
from a RTT mouse model.
Conclusion: Initial expression profiling from T-cell clones of RTT patients identified a list of
potential MeCP2 target genes. Further detailed analysis and comparison to independent microarray
experiments did not confirm significantly altered expression of most candidate genes. These results
are consistent with other reported data.
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Background
Rett syndrome (RTT, OMIM 312750) is an X-linked neu-
rodevelopmental disorder that affects 1 in 10,000 to
15,000 females [1,2]. Girls with RTT have an apparently
normal early development, followed by deceleration of
head growth, loss of language skills, loss of purposeful
hand movements and impaired social contact. As the dis-
ease progresses they develop respiratory abnormalities,
autistic features, stereotypic hand movements, scoliosis,
general growth delay, seizures and ataxia [3,4]. RTT is
caused by heterozygous mutations in the methyl-CpG-
binding protein 2 gene (MECP2), an X-linked gene subject
to X chromosome inactivation (XCI) [5]. Mutations in the
coding region of this gene are detected in 85% of patients
with classic RTT [6-9]. An additional 10% have large dele-
tions affecting several exons of MECP2 [10-12]. Alterna-
tive splice variants of MECP2  have been identified
[9,13,14] that result in two protein isoforms. MeCP2-e1
(MeCP2α/B) is encoded by exons 1, 3 and 4 and is more
abundant in brain than the previously identified MeCP2-
e2 (MeCP2β/A) isoform, which is encoded by exons 2, 3
and 4. Interestingly, mutations in exon 1 are only rarely
found in RTT patients [9,15,16]. Both isoforms of MeCP2
are identical beyond exon 2 and contain an 84-amino acid
methyl-CpG-binding domain [17] and a 104-amino acid
transcriptional repression domain (TRD) [18] as well as a
C-terminal protein interaction domain. MeCP2 has been
shown to bind DNA, preferentially at methylated CpG
dinucleotides with resulting transcriptional repression of
nearby genes through the recruitment of a histone
deacetylase (HDAC1 and 2) and a Sin3A-containing core-
pressor complex [19,20]. MeCP2 also associates with his-
tone methyltransferase activity and the DNA
methyltransferase DNMT1 [21,22]. Brahma (Brm), the
catalytic component of the SWI/SNF ATPase-dependent
remodelling complex, was found to interact with MeCP2
[23], extending the mechanistic link between DNA meth-
ylation, chromatin remodelling and transcriptional
repression. Recently, MecP2 has also been demonstrated
to regulate alternative splicing and interact with an RNA-
binding protein (Y box-binding protein 1) [24].
Despite active research since the discovery of MECP2
mutations in RTT, it has proven difficult to identify other
direct target genes for the proposed functions of MeCP2.
Candidate gene-based approaches using vertebrate mod-
els with disrupted MeCP2 have resulted in the identifica-
tion of brain-derived neurotrophic factor (Bdnf) [25-27]
and Hairy2a [28] as MeCP2 targets. MeCP2 binds to meth-
ylated CpG sites near promoter III of BDNF in resting neu-
rons [25,26], and disease progression in a RTT mouse
model correlates inversely with Bdnf expression [27].
Hairy2a is upregulated in the absence of MeCP2 in Xeno-
pus embryos [28]. Following the hypothesis that MeCP2
functions primarily as a transcriptional repressor, several
groups have attempted to screen for its targets by tran-
scriptional profiling using RNA from postmortem brain
tissues or cell lines derived from RTT patients, or from tis-
sues of mice with engineered mutations in Mecp2. In one
study, 70 transcripts were found to have altered gene
expression in mutant versus wild-type fibroblast clones
and lymphoblastoid cells lines [29]. The authors con-
cluded that MeCP2 deficiency did not lead to global
deregulation of gene expression and suggested that clonal
fibroblast lines may show substantial variation, making
them an unstable resource for expression profiling stud-
ies. In addition, lymphoblastoid cell lines are immortal-
ized by Epstein-Barr virus (EBV) transformation, which
can alter their transcriptional profile and methylation sta-
tus. Expression profiling of brain from male mice with a
deletion of Mecp2 also yielded only few genes with altered
expression between wild-type and mutant mice [30].
Upon further analysis, those identified fell well within the
range of the high false-positive rate [30]. In a third tran-
scriptional profiling microarray study on postmortem RTT
brains, significant changes in expression for 135 genes on
three different cDNA microarrays were found [31]. Yet,
the small sample size analyzed and the validation of the
array data with the same samples instead of independent
samples may have led to false-positive results [30]. It has
been hypothesized that transcriptional profiling of
MECP2-deficient brains has failed to identify MeCP2-reg-
ulated genes because of the high complexity in regional
organization and the admixture of neuronal and non-
neuronal cell types that is inherent to brain tissue [32].
Perhaps MeCP2 targets are also difficult to identify by
microarray analysis because the absolute changes in
expression level for individual genes are very small [33]. A
more direct approach that circumvents this problem is the
use of a chromatin immunoprecipitation (ChIP) strategy
to directly search for the sites of MeCP2-binding to DNA.
This led to the recent identification of the DLX5 gene as a
MeCP2 target and other genes such as CNTN2, FOXA3,
and SIAT4A as candidate genes regulated by MeCP2 [34].
In the present study we sought to overcome some of the
limitations of transcriptional profiling on complex tis-
sues, such as brain, as well as those of transformed lym-
phoblastoid cell lines by studying clonal cultures of non-
transformed lymphocytes from individual RTT patients.
These cells can be easily obtained through blood sam-
pling, readily cultured and subjected to single-cell sub-
cloning. Because MECP2 undergoes XCI, this last feature
allows the separation of cells that express the wild-type
MECP2 from the active X from those cells that express the
mutant MECP2 from the active X. To identify downstream
targets of MeCP2, we compared global gene expression
patterns in matched pairs of clonally derived mutant or
wild-type  MECP2-expressing lymphocyte cultures from
two girls with classic Rett syndrome. Our microarray anal-BMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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ysis revealed 121 genes with changes in expression
between cells expressing the wild-type MECP2 and those
expressing the mutant MECP2. We compared this gene list
to those of other transcriptional profiling experiments
and focused further analysis on a downregulated putative
MeCP2 target, SPOCK1. However, quantitative RT-PCR
analysis on RNA from the clonal T-lymphocytes, differen-
tiating mouse embryoid bodies (EB) and various mouse
brain regions did not reveal significantly different expres-
sion between mutant and wild-type RNAs.
Methods
T-lymphocyte single cell cloning
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Hypaque from fresh blood samples of Rett
syndrome patients, collected under a research protocol
approved by the Baylor College of Medicine Institutional
Review Board for Human Subjects Research. Isolation of
T-lymphocyte clones has been described previously [35-
37]. Briefly, PBMCs from the patients were plated at lim-
iting dilution in 96-well plates in the presence of irradi-
ated allogeneic PBMCs in RPMI media containing 20%
pooled human sera (Sigma-Aldrich, St. Louis, MO), 2 μg/
mL PHA.P (Murex diagnostics, Inc. Dartford Kent, UK)
and 5% Human T-stim (Collaborative Biomedical Prod-
ucts, Bedford, MA). Nine to ten days following original
culture, wells showing clonal positive growth were restim-
ulated and cultured for an additional 7–14 days. Addi-
tional restimulations were performed every 10–12 days
until >107 cells were obtained from each clone.
RNA isolation and reverse transcription
Total RNA was isolated from T-cell clones using Trizol rea-
gent (Invitrogen Corp., Carlsbad, CA). RNA was treated
with 1 U of RNase-free DNase I (Ambion Inc., Austin, TX).
RNA samples were stored at -80°C until later use. Analysis
of allelic expression of MECP2 by RT-PCR and restriction
digestion to verify clonality of expanded lymphocyte
clones from patients RT208 (c.1308-1309delTC muta-
tion) and RT211 (p.T158M mutation) has been previ-
ously described [37].
Animal research was performed under a protocol
approved by the Baylor College of Medicine animal
research review board. After euthanasia, brain regions
(cortex, cerebellum, olfactory bulb) were quickly removed
from 5 week-old mice and immediately frozen in liquid
nitrogen. E16.5 embryos were collected and heads and
bodies immediately frozen in liquid nitrogen. Total RNA
was extracted using the Qiagen RNeasy Mini kit (Qiagen
Inc., Valencia, CA). Prior to array hybridization, the RNA
quality and degradation was verified using the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
In addition, quality control parameters were assessed
throughout the experimental process to assure the effi-
ciency of transcription, integrity of hybridization, and
consistency of qualitative calls. Assessment during the
synthesis of the hybridization transcript was accom-
plished by spectrophotometric analysis of the starting
RNA and cRNA, and by gel electrophoresis following syn-
thesis of the cDNA, cRNA and fragmentation of the cRNA.
A 3'/5' ratio of GAPDH less than 2 was considered accept-
able for efficiency of transcription. Spiked control tran-
scripts were also monitored to verify hybridization
integrity. Scaling factors for each sample ranged between
1.72 and 5.39. All quality control measures were consist-
ent with the manufacturers recommended procedures and
conformed to the recommended cut-off values except for
one of the RT211 (p.T158M) wild-type clonal lymphocyte
samples (Wt5) which was not included in subsequent
analysis because the RNA was found to be partially
degraded.
Oligonucleotide expression array hybridization
Total RNA was converted to double-stranded cDNA (ds-
cDNA) in the presence of an oligo-dT primer containing a
T7 RNA polymerase promoter. In vitro transcription was
performed to generate biotin-labeled cRNA from the ds-
cDNA template in the presence of a mixture of biotin-
labeled ribonucleotides. Biotin-labeled cRNA (15 μg) was
fragmented to a size range between 50–200 bases in
length and used to hybridize to Affymetrix human HG-
U133A chips. After hybridization, the arrays were washed
and stained with Streptavidin-phycoerythrin. Arrays were
read at a resolution of 3 microns using a HP Gene Array
Scanner (Hewlett Packard, Inc., Palo Alto CA) The average
background for each chip was determined to be below the
common threshold of 100 for all analyzed chips.
Microarray data analysis
For the array hybridizations with RNA from clonal lym-
phocyte cultures, raw data was obtained from an HP Gene
Array Scanner and normalized by the GC Robust Multi-
chip Average or GC-RMA analysis. Briefly, in RMA analysis
[38,39], described by Irazarry et al. [40,41], the back-
ground correction is based on the distribution of probe
mismatch (MM) values amongst all probes on the array
and compensates for non-specific binding using "perfect
match" (PM) distributions rather than PM-MM values.
The RMA method uses probe-level multichip quantile
normalization to unify PM distributions across all chips
and robust probe-set summary of the log-normalized
probe-level data by median polishing. GC-RMA is similar
to RMA, except that it reduces the bias of not substracting
MM values in the background correction by an algorithm
that takes into account that the non-specific affinity of a
probe is related to its sequence [39,42]. GC-RMA normal-
izations were performed using GeneSpring GX 7.3.1 soft-
ware (Agilent Technologies, Palo Alto, CA) with default
parameters as follows: values below 0.01 were set to 0.01;BMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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each measurement was divided by the 50.0th percentile of
all measurements in that sample; each gene was divided
by the median of its measurements in all samples; if the
median of the raw values was below 10 then each meas-
urement for that gene was divided by 10 if the numerator
was above 10, otherwise the measurement was thrown
out. Log2-transformed data files from all GC-RMA nor-
malizations were analyzed for significance using the
GeneSpring GX 7.3.1 software with the most recent anno-
tations of the HG-U133A human genome chip. Samples
from 9 chips were divided in 4 groups according to geno-
type (wild-type versus mutant) and specific patient
(RT211 with the p.T158M mutation versus RT208 with
the c.1308-1309delTC). As outlined above, we excluded
one wild-type chip (Wt5) from analysis because of poor
RNA quality (Figure 1). Parametric testing (one-way
ANOVA with a p-value cut-off of <0.05) was used; vari-
ances were calculated with the cross-gene error model.
When multiple-testing correction was performed, the Ben-
jamini-Hochberg false discovery rate (FDR) analysis was
used. The lists were also filtered for two-fold and 1.5-fold
up or down-regulation.
Gene lists of all up and downregulated genes at the p <
0.05 level were then compared to lists of genes from anal-
ysis of another transcriptional profiling experiment in
progress in our laboratory that compares gene expression
profiles of Mecp2R308/Y-mutant [43] and wild-type embry-
oid bodies (EB) at day 5 after retinoic acid-induced in vitro
differentiation of mouse embryonic stem cells (unpub-
lished data). We also compared the gene lists from the
clonal lymphocyte cultures to those from previously pub-
lished microarray experiments on RNA samples of Rett
syndrome patients or of Mecp2-mutant mouse models
[29-31,44], and genes found to be MeCP2-targets by chro-
matin immunoprecipitation experiments [34]. To allow
direct comparison of all different datasets using consistent
nomenclature, we replaced the gene annotations in all
these lists with the official symbol for the human genes
(or human orthologue of mouse genes) from the NCBI
Entrez Gene browser [45] (See additional file 1: supple-
mentary table 1).
Quantitative real-time PCR
For quantitative real-time PCR on mouse tissues, an equal
amount of total RNA isolated from brain regions (cortex,
cerebellum and olfactory bulb) of 5 week-old mice or
E16.5 embryos was converted to cDNA with SuperScript II
reverse transcriptase (Invitrogen Corp., Carlsbad, CA). For
quantitative real-time PCR on human samples, total RNA
from the clonal lymphocyte cultures used for microarray
hybridization was similarly converted to cDNA. We used
the ABI Prism 7300 sequence detection system (Applied
Biosystems, Foster City, CA) to perform quantitative real
time PCR with SYBR Green as the detection agent. The
primers used were as follows. Murine Spock1
(NM_009262): Spock1 forward primer: TGCACGGACAAG-
GAGCTGCG,  Spock1  reverse primer: GAACCAGTCCT-
TCAGCCGG; Murine Gapdh  (NM_001001303):  Gapdh
forward primer: CATGGCCTTCCGTGTTCCTA, Gapdh
reverse primer: GCGGCACGTCAGATCCA; human
SPOCK1  (NM_004598):  SPOCK1  forward primer:
TGCACAGACAAGGAGTTGCG,  SPOCK1  reverse primer:
AAACCAATCCTTCAGCCGG; human GAPDH
(NM_002046):  GAPDH  forward primer: TGGGCTA-
CACTGAGCACCAG, and GAPDH reverse primer: GGGT-
GTCGCTGTTGAAGTCA. After PCR amplification, a
dissociation protocol was performed to determine the
melting curve of the PCR product. Only reactions with
melting curves indicative of a single amplification product
were analyzed further. The identity and expected size of
the single PCR product was also confirmed by agarose gel
electrophoresis. Relative quantification of the abundance
of each gene at every time point was performed by the
comparative  ΔΔCT method as described in the Applied
Biosystem user bulletin #2 [46]. The values obtained by
this method are a measure of the fold-change in expres-
sion of the gene of interest compared to the calibrator
sample, all normalized to Gapdh  (mouse samples) or
GAPDH (human samples). The Student's t test was used to
determine statistical significance of expression differences
between average CT values of wild-type and mutant sam-
ples. A p-value < 0.05 was considered significant.
Experimental design of T-lymphocyte clone isolation Figure 1
Experimental design of T-lymphocyte clone isolation. 
Two technical replicate hybridizations for the wild type 
MECP2 and mutant MECP2-expressing clonal cell-cultures 
(RT211 with p.T158M mutation and RT208 with c. 1308-
1309delTC mutation) were performed, as well as a biological 
replicate hybridization with an independent clone of patient 
RT211. (PBLy = peripheral blood lymphocytes; Ly clone = T-
lymphocyte clone; * indicates unused in array hybridization 
analysis because of insufficient RNA quality)
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Results
Isolation of MECP2-mutant and MECP2-wild type T-
lymphocyte clones
Because MECP2 is an X-linked gene that undergoes XCI in
females, each cell expresses MECP2 exclusively from only
one of the two X chromosomes (the active X), while the
copy of the gene on the inactive X chromosome is
silenced. In order to separate cells that express the wild
type MECP2 from those that express the mutant MECP2
allele, we performed single-cell cloning of T-lymphocytes
isolated from peripheral blood mononuclear cells of RTT
patients [37]. To allow for comparison between two types
of mutations, samples from two girls with classic RTT, one
(RT211) with a p.T158M missense mutation and one
(RT208) with a c.1308-1309delTC frameshift mutation,
were used for this experiment. Following two rounds of
mitogenic stimulation, all clonal cultures with greater
than 107 cells were harvested for RNA isolation. As previ-
Table 1: Genes with lower expression in mutant samples on microarray analysis. This table contains a list of genes with lower 
expression in mutant T-lymphocyte clones by one-way ANOVA analysis (p < 0.05). * indicates >1.5-fold change in expression level and 
** indicates >2-fold change in expression level.
No. Gene Name P-value Common name Genbank No. Description
1** 201160_s_at 0.000593 CSDA AL556190 cold shock domain protein A
2* 201417_at 0.00108 SOX4 AL136179 SRY (sex determining region-Y) box 4
3 202565_s_at 0.00385 SVIL NM_003174 supervillin
4 204860_s_at 0.00453 BIRC1 AI817801 Transcribed seq with strong similarity BIR1
5 215333_x_at 0.00459 GSTM1 X08020 glutathione S-transferase M1
6* 210763_x_at 0.00546 NCR3 AF031137 natural cytotoxicity triggering receptor 3
7** 217979_at 0.00821 TM4SF13 NM_014399 transmembrane 4 superfamily member 13
8 208524_at 0.0117 GPR15 NM_005290 G protein-coupled receptor 15
9** 215440_s_at 0.012 BEXL1 AL523320 hypothetical protein FLJ10097
10 213193_x_at 0.0157 TRBC1 AL559122 T cell receptor beta chain BV20S1 BJ1-5 BC1 mRNA
11 220131_at 0.0174 FXYD7 NM_022006 FXYD domain containing ion transport regulator 7
12 204550_x_at 0.0175 GSTM1 NM_000561 glutathione S-transferase M1
13 212739_s_at 0.0186 NME4 AL523860 non-metastatic cells 4, protein expressed in
14* 220684_at 0.0187 TBX21 NM_013351 T-box 21
15 203030_s_at 0.0195 PTPRN2 AF007555 protein tyrosine phosphatase, receptor type N polypeptide 2
16 219693_at 0.0232 AGPAT4 NM_020133 1-acylglycerol-3-phosphate O-acyltransferase 4
17* 219654_at 0.0245 PTPLA NM_014241 protein tyrosine phosphatase-like, member a
18 217764_s_at 0.0245 RAB31 AF183421 RAB31, member RAS oncogene family
19* 217671_at 0.0247 RFX3 BE466926 regulatory factor X, 3 (Influences HLA class II expression)
20** 204232_at 0.025 FCER1G NM_004106 Fc fragment of IgE, high affinity receptor for γ-polypeptide
21* 1405_i_at 0.0298 CCL5 M21121 chemokine (C-C motif) ligand 5
22** 206170_at 0.0308 ADRB2 NM_000024 adrenergic, beta-2-, receptor, surface
23** 211583_x_at 0.0317 NCR3 AF031136 natural cytotoxicity triggering receptor 3
24 202279_at 0.0328 C14orf2 NM_004894 chromosome 14 open reading frame 2
25 214012_at 0.0333 ARTS-1 BE551138 type 1 TNF receptor shedding aminopeptidase regulator
26 204396_s_at 0.0346 GRK5 NM_005308 G protein-coupled receptor kinase 5
27** 211010_s_at 0.0349 NCR3 AF031138 natural cytotoxicity triggering receptor 3
28 208791_at 0.0351 CLU M25915 clusterin
29** 219529_at 0.0383 CLIC3 NM_004669 chloride intracellular channel 3
30 217104_at 0.0385 LOC283687 AL109714 hypothetical protein LOC283687
31 213280_at 0.0397 GARNL4 AK000478 GTPase activating RANGAP domain-like 4
32 202234_s_at 0.04 SLC16A1 BF511091 solute carrier family 16, member 1
33** 215006_at 0.0404 AK023816 CDNA FLJ13754 fis, clone PLACE3000362
34 204883_s_at 0.0409 HUS1 AI968626 HUS1 checkpoint homolog (S. pombe)
35** 217963_s_at 0.0409 NGFRAP1 NM_014380 nerve growth factor receptor (TNFRSF16) ass. protein 1
36** 212070_at 0.0419 GPR56 AL554008 G protein-coupled receptor 56
37** 202363_at 0.042 SPOCK1 AF231124 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican)
38* 206974_at 0.0427 CXCR6 NM_006564 chemokine (C-X-C motif) receptor 6
39 200965_s_at 0.0433 ABLIM1 NM_006720 actin binding LIM protein 1
40 219457_s_at 0.045 RIN3 NM_024832 Ras and Rab interactor 3
41** 213915_at 0.0452 NKG7 NM_005601 natural killer cell group 7 sequence
42 215411_s_at 0.0463 C6orf4 AL008730
43* 212274_at 0.0484 LPIN1 AV705559 AV705559ADB Homo sapiens cDNA clone ADBAPE04 5'
44 219155_at 0.049 PITPNC1 NM_012417 phosphatidylinositol transfer protein, cytoplasmic 1BMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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ously reported for these cell cultures, RT-PCR followed by
digestion of the amplified products to completion with
restriction enzymes specific for the mutant allele, demon-
strated that we had obtained pure populations of clonal
cells, expressing either a mutant or a wild-type MECP2
[37].
Microarray analysis of matched lymphocyte clones
Two technical replicate hybridizations were performed for
one of each clone type, as well as an additional biological
replicate hybridization for the wild-type MECP2  and
mutant  MECP2  clones of RT211 (p.T158M) on HG-
U133A human genome chips containing 22,283 genes
(Affymetrix, Santa Clara, CA) (Figure 1). Signals of all
hybridized chips were normalized using the GC-RMA
method [42]. We then performed one-way ANOVA analy-
sis to find genes with significantly altered expression in
Mut2 and Mut4 from patient RT208 (c.1308-1309delTC),
and Mut1, Mut3 and Mut5 from patient RT211
(p.T158M) compared to WT2 and WT4 from patient
RT208, and WT1 and WT3 from patient RT211.
One-way ANOVA analysis, with a p < 0.05 yielded a total
of 121 genes with significantly different expression
between wild-type and mutant samples. Of these, 44 had
a reduced level of expression (Table 1) and 77 had an
increased level of expression (Table 2) in mutant com-
pared to wild-type clones. When these lists were filtered
for absolute fold-expression change, there were 28 genes
with 1.5 fold higher expression in mutant compared to
wild-type (13 genes with 2-fold higher expression) and 21
genes with 1.5 fold lower expression in mutant compared
to wild-type (12 genes with 2-fold lower expression). It is
however important to note that, although these expres-
sion changes are statistically significant at a cut-off of p <
0.05, 1,134 (5%) of the 22,283 genes present in the HG-
U133A chip, would randomly be expected to show altered
expression. In addition, FDR analysis using the Ben-
jamini-Hochberg algorithm did not retain any genes with
significantly altered expression. Because FDR analysis may
be too stringent for genes with low-level expression, we
next determined if any of the 121 genes found to have
altered expression without the FDR correction might be
more relevant to Rett syndrome. We compared our data to
those of other published expression microarray experi-
ments [29-31,44], to a published list of putative direct
MeCP2 targets found by chromatin immunoprecipitation
[34], and to results from another ongoing microarray
experiments in our laboratory that compares murine EBs
with a truncating Mecp2 mutation (Mecp2R308/Y) to wild-
type EBs at day 5 after retinoic-acid induced in vitro differ-
entiation of mouse ES cells (unpublished data). Very lim-
ited overlap was found between each of these lists (See
additional file 2: Supplementary table 2). One downregu-
lated gene, BEXL1, encoding brain expressed X-linked-like
1, a protein of unknown function of the BEX family of
proteins [47], was also found downregulated in the
expression profiling performed by Traynor et al. [29].
However, its expression was not altered in our microarray
experiments on Mecp2R308/Y mutant samples compared to
wild-type differentiating mouse EBs, and it was not prior-
itized for further analysis. In contrast, two genes, LPIN1
and SPOCK1 with significantly reduced expression in this
microarray analysis also showed lower expression in
Mecp2R308/Y mutant samples compared to wild-type in our
microarray experiments on differentiating mouse EBs.
LPIN1 encodes lipin, a protein important for adipocyte
differentiation and function that plays a role in glucose
and lipid homeostasis and has been associated with
human lipodystrophy [48,49]. Based on this known func-
tion, we considered it a less likely candidate for an impor-
tant role in the neurological phenotype of RTT. We
focused on SPOCK1, the only gene found downregulated
in our own two microarray experiments that has a func-
tion that is compatible with a possible role in the RTT phe-
notype. SPOCK1 encodes the 439-amino acid SPOCK1
protein (Sparc/osteonectin-like domains, CWCV and
Kazal-like domains proteoglycan 1 precursor), also
known as Testican [50]. It is a predominantly extracellular
matrix chondroitin sulphate-linked proteoglycan that is
related to protein families that have protease inhibitor
function and are involved in cell adhesion, migration, and
proliferation. Human SPOCK1 and mouse Spock1 share
95% identity. SPOCK1 is highly enriched in neurons and
endothelial cells of the central nervous system, absent in
quiescent astroglia, but upregulated in activated astroglia
[51]. Mouse Spock1 is highly expressed at the start of neu-
rogenesis during neuron migration and axonal outgrowth
and subsequently in developing synaptic fields [52].
Spock1 has also been found to inhibit adhesion and neu-
rite outgrowth of cultured Neuro2A cells [53]. In the
adult, it localizes predominantly to the postsynaptic
region of a subpopulation of pyramidal neurons in the
CA3 region of the hippocampus [54]. These features sug-
gested a possible role in motor or behavioural aspects of
the RTT phenotype. Therefore, we focused on this gene for
further analysis.
Expression of the mouse orthologue of SPOCK1 is not 
altered in a RTT mouse model
Although not statistically significant, a trend for lower
expression was found by qPCR analysis using the RNAs
from the clonal lymphocyte cultures that were used to per-
form the microarray hybridizations, but no difference was
seen in RNAs from differentiating wild-type and mutant
mouse EBs (Figure 2A). To test if there is altered expres-
sion in the brain, the organ most affected by RTT-causing
mutations, we performed qPCR reactions on RNA sam-
ples from mutant Mecp2308/Y and wild-type cerebral cor-
tex, cerebellum and olfactory bulb from 5 week old miceBMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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Table 2: Genes with higher expression in mutant samples on microarray analysis. This table contains a list of genes with higher 
expression in mutant T-lymphocyte clones by one-way ANOVA analysis (p < 0.05). * indicates >1.5-fold change in expression level and 
** indicates >2-fold change in expression level.
No. Gene Name P-value Common name Genbank No. Description
1 219759_at 6.66E-11 LRAP NM_022350 leukocyte-derived arginine aminopeptidase
2 206148_at 0.000152 IL3RA NM_002183 interleukin 3 receptor, alpha (low affinity)
3* 213655_at 0.000209 YWHAE AA502643 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein
4* 212952_at 0.000278 MNT AA910371 calreticulin
5 218340_s_at 0.000346 FLJ10808 NM_018227 hypothetical protein FLJ10808
6* 200765_x_at 0.000507 CTNNA1 NM_001903 catenin (cadherin-associated protein), alpha 1, 102 kDa
7* 210732_s_at 0.000704 LGALS8 AF342816 lectin, galactoside-binding, soluble, 8 (galectin 8)
8 219974_x_at 0.00131 ECHDC1 NM_018479 enoyl Coenzyme A hydratase domain containing 1
9 202732_at 0.00142 PKIG NM_007066 protein kinase (cAMP-dependent, catalytic) inhibitor γ
10 204418_x_at 0.00183 GSTM4 NM_000848 glutathione S-transferase M2 (muscle)
11 221754_s_at 0.00187 CORO1B AI341234 coronin, actin binding protein, 1B
12* 219648_at 0.00266 FLJ10116 NM_018000 hypothetical protein FLJ10116
13* 212099_at 0.00528 RHOB AI263909 ras homolog gene family, member B
14 213135_at 0.00579 TIAM1 U90902 T-cell lymphoma invasion and metastasis 1
15** 210844_x_at 0.00603 CTNNA1 D14705 catenin (cadherin-associated protein), alpha 1, 102 kDa
16 208743_s_at 0.00617 YWHAB BC001359 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein
17* 204201_s_at 0.00621 PTPN13 NM_006264 protein tyrosine phosphatase, non-receptor type 13
18* 222146_s_at 0.00628 TCF4 AK026674 transcription factor 4
19* 214130_s_at 0.00717 PDE4DIP AI821791 phosphodiesterase 4D interacting protein (myomegalin)
20** 211893_x_at 0.00833 CD6 U66145 CD6 antigen
21** 210136_at 0.00975 MBP AW070431 myelin basic protein
22** 209012_at 0.0106 TRIO AV718192 triple functional domain (PTPRF interacting)
23 222173_s_at 0.0109 TBC1D2 AK026105 TBC1 domain family, member 2
24 218435_at 0.0112 DNAJD1 NM_013238 DnaJ (Hsp40) homolog, subfamily D, member 1
25 210354_at 0.0122 IFNG M29383 Human mRNA for HuIFN-gamma interferon.
26 217744_s_at 0.0132 PERP NM_022121 PERP, TP53 apoptosis effector
27* 213822_s_at 0.0133 UBE3B BE856776 ubiquitin protein ligase E3B
28 204412_s_at 0.015 NEFH NM_021076 neurofilament, heavy polypeptide 200 kDa
29 200862_at 0.0151 DHCR24 NM_014762 24-dehydrocholesterol reductase
30 210949_s_at 0.0153 EIF3S8 BC000533 eukaryotic translation initiation factor 3, subunit 8, 110 kDa
31 218393_s_at 0.0172 SMU1 NM_018225 homolog of C. elegans smu-1
32 221550_at 0.018 COX15 BC002382 COX15 homolog, cytochrome c oxidase assembly protein
33* 203413_at 0.0192 NELL2 NM_006159 NEL-like 2 (chicken)
34 221036_s_at 0.0192 PSFL NM_031301 anterior pharynx defective 1B-like
35* 210915_x_at 0.0208 PRSS1 M15564 T-cell receptor precursor
36 218943_s_at 0.0212 DDX58 NM_014314 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide
37 207813_s_at 0.0215 FDXR NM_004110 ferredoxin reductaseBMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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38 221021_s_at 0.0216 CTNNBL1 NM_030877 catenin, beta like 1
39 214316_x_at 0.0216 MNT AI378706 Calreticulin
40** 209728_at 0.022 HLA-DRB4 BC005312 major histocompatibility complex, class II, DR beta 3
41 215230_x_at 0.0229 EIF3S8 AA679705 eukaryotic translation initiation factor 3, subunit 8, 110 kDa
42 219269_at 0.024 FLJ21616 NM_024567 hypothetical protein FLJ21616
43** 207533_at 0.0246 CCL1 NM_002981 chemokine (C-C motif) ligand 1
44 207275_s_at 0.0255 ACSL1 NM_001995 acyl-CoA synthetase long-chain family member 1
45 217856_at 0.0274 RBM8A AF182415 RNA binding motif protein 8A
46 200647_x_at 0.0277 EIF3S8 NM_003752 eukaryotic translation initiation factor 3, subunit 8, 110 kDa
47* 214395_x_at 0.028 PP3856 AI335509 eukaryotic translation elongation factor 1 delta
48** 211900_x_at 0.0297 CD6 U66146 CD6 antigen
49 215606_s_at 0.0307 ELKS AB029004 Rab6-interacting protein 2
50 218945_at 0.0311 MGC2654 NM_024109 hypothetical protein MGC2654
51 209790_s_at 0.0314 CASP6 BC000305 caspase 6, apoptosis-related cysteine protease
52 201143_s_at 0.0325 EIF2S1 BC002513 eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDa
53 211965_at 0.0332 ZFP36L1 BE620915 zinc finger protein 36, C3H type-like 1
54** 201242_s_at 0.0339 ATP1B1 BC000006 ATPase, Na+/K+ transporting, beta 1 polypeptide
55 213388_at 0.0346 PDE4DIP H15535 ym27c01.s1 Soares infant brain 1NIB cDNA clone IMAGE:49385 3'
56 214182_at 0.036 ARF6 AA243143 ADP-ribosylation factor 6
57 212190_at 0.0362 SERPINE2 AL541302 AL541302 Homo sapiens PLACENTA cDNA clone CS0DE006YI10 5'
58* 204015_s_at 0.0365 DUSP4 BC002671 dual specificity phosphatase 4
59** 206366_x_at 0.0372 XCL1 U23772 chemokine (C motif) ligand 1
60* 216609_at 0.0374 TXN AF065241 Thioredoxin
61 219836_at 0.038 ZBED2 NM_024508 zinc finger, BED domain containing 2
62** 208602_x_at 0.0383 CD6 NM_006725 CD6 antigen
63** 208302_at 0.0385 HB-1 NM_021182 minor histocompatibility antigen HB-1
64 209433_s_at 0.0393 PPAT AI457120 phosphoribosyl pyrophosphate amidotransferase
65** 221618_s_at 0.0404 TAF9L AF220509 TAF9-like RNA polymerase II
66 202807_s_at 0.0427 TOM1 NM_005488 target of myb1 (chicken)
67 222145_at 0.043 AK027225 Similar to PI-3-kinase-related kinase SMG-1 isoform 1; (LOC390682)
68** 212599_at 0.0435 AUTS2 AK025298 autism susceptibility candidate 2
69 209392_at 0.0447 ENPP2 L35594 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)
70 204137_at 0.0453 TM7SF1 NM_003272 transmembrane 7 superfamily member 1 (upregulated in kidney)
71 209015_s_at 0.0455 DNAJB6 BC002446 DnaJ (Hsp40) homolog, subfamily B, member 6
72 209013_x_at 0.0482 TRIO AF091395 triple functional domain (PTPRF interacting)
73 215920_s_at 0.0488 LOC283970 AC002544
74 221069_s_at 0.0492 LOC51204 NM_016360 clone HQ0477 PRO0477p
75 214741_at 0.0494 ZNF131 AW968301 zinc finger protein 131 (clone pHZ-10)
76 207485_x_at 0.0495 BTN3A1 NM_007048 butyrophilin, subfamily 3, member A1
77 220937_s_at 0.0496 SIAT7D NM_014403 sialyltransferase 7D
Table 2: Genes with higher expression in mutant samples on microarray analysis. This table contains a list of genes with higher 
expression in mutant T-lymphocyte clones by one-way ANOVA analysis (p < 0.05). * indicates >1.5-fold change in expression level and 
** indicates >2-fold change in expression level. (Continued)BMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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Quantitative RT-PCR (qPCR) analysis of Spock1 expression Figure 2
Quantitative RT-PCR (qPCR) analysis of Spock1 expression. Quantitative RT-PCR analysis of the expression of (A.) 
human SPOCK1 in the clonal lymphocyte RNAs (Mt Ly, Wt Ly) used for the microarray experiments and of mouse Spock1 in 
differentiating wild-type (Wt EB) and Mecp2R308/Y mutant (Mt EB) male mouse embryoid bodies; (B.) cerebral cortex (Wt Cx, 
Mt Cx), cerebellum (Wt Cb, Mt Cb) and olfactory bulb (Wt OB, Mt OB) of adult (5 week-old) wild-type and Mecp2R308/Y 
mutant male mice; and (C.) E16.5 embryo head (Wt head, Mt head) and body (Wt body, Mt body) (4 independent samples 
were tested for each tissue and genotype). The Y-axis shows the average fold change in expression +/- standard deviation) of 
mutant compared to wild-type, which is set as one-fold baseline, except for the Ly samples, where the one-fold baseline was 
set in the mutant for figure clarity (light bars = wild-type; dark bars = mutant), p-values are given under each respective graph.
Wt Ly Mt Ly
1
2
3
4
5
6
Wt EB Mt EB
0.5
1.0
1.5
2.0
2.5
Wt OB Mt OB
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Wt Cx Mt Cx
0.5
1.0
1.5
2.0
2.5
3.0
Wt Cb Mt Cb
0.25
0.50
0.75
1.00
1.25
1.50
A.
B.
p=0.52 p=0.72
p=0.12 p=0.06 p=0.51
Wt Body Mt Body
0.25
0.50
0.75
1.00
1.25
Wt Head Mt Head
0.25
0.50
0.75
1.00
1.25
1.50
1.75
C.
p=0.62 p=0.34BMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
Page 10 of 13
(page number not for citation purposes)
(Figure 2B), as well as on heads and bodies from wild-type
and mutant E16.5 embryos (Figure 2C). No statistically
significant differences in expression of Spock1  between
any of these mutant and wild type samples were detected.
Discussion
Heterozygous mutations in X-linked MECP2 are found in
most girls with RTT. The MECP2 gene is subject to XCI and
classic RTT patients typically have random XCI patterns
[55,56]. Hence, patients with RTT have a mosaic distribu-
tion of cells expressing the wild-type MECP2 and cells
expressing the mutant MECP2 allele in all of their tissues.
Analysis of gene expression profiles on tissues from
deceased girls with RTT will therefore be compromised by
unpredictable patterns of XCI. In addition, the presence of
functional "wild-type" cells will also dampen small effects
on the expression levels of MeCP2 target genes. Postmor-
tem tissues are mostly from girls at later stages of the dis-
order and their gene expression profiles may reflect the
presence of concurrent disease.
Because central nervous system neurons are the primary
cell types where the RTT syndrome pathology occurs, a
pure population of neurons with the mutant MECP2 on
the active X chromosome, compared to one with the wild-
type MECP2 on the active X chromosome from the same
individual would constitute an ideal sample set for analy-
sis of gene expression profiles in the presence of MECP2
mutations, but such samples are unavailable from human
patients and alternative strategies are needed.
MECP2 is expressed, albeit at lower levels, in nearly all
other tissues, including T-lymphocytes. Although T-lym-
phocytes are not the primary cell type where the RTT phe-
notype manifests, previous experiments have shown that
lymphocytes with the mutant MECP2  on the active X
chromosome are at a growth disadvantage compared to
those with the wild-type MECP2 on the active X chromo-
some [37]. This suggested to us that at least a subset of the
MeCP2 target genes are dysregulated in this cell type and
pure T-lymphocyte clonal cell lines may be a valuable
source of RNA for gene expression profiling in Rett syn-
drome.
We isolated single T-lymphocytes from blood samples of
RTT patients and clonally expanded them in order to com-
pare MECP2 mutant and wild type expression in the same
patient. Since only one form of MECP2  would be
expressed in each isolated clone, we expected that effects
on gene expression profiles would be more pronounced.
Furthermore, by comparing these clonal T-lymphocytes
from the same patient, we could eliminate changes result-
ing from interindividual genetic differences. A similar
approach was taken by Traynor et al., 2002, but instead of
lymphocytes they used lymphoblastoid cell lines and
fibroblast clones [29]. Lymphoblastoid cells have the dis-
advantage that they are immortalized which can affect
gene expression patterns, while fibroblast cultures can
gain epigenetic differences as they divide in culture.
Although the T-lymphocytes used in our experiment were
also cultured, the number of cell divisions was small and
the cells were not transformed.
Because we did not study the primary cell type that is
responsible for the RTT pathology, we strove to increase
the likelihood that any observed differences in gene
expression levels between mutant and wild-type MECP2-
expressing clones were relevant to Rett syndrome. We
used samples from patients with two different types of
mutations (p.T158M and c.1308-1309delTC), combined
the results from these samples to focus only on genes with
a consistent pattern of increased or decreased levels of
expression in all mutant clones compared to wild type.
We next compared these results to those of our other inde-
pendent microarray experiment on Mecp2-mutant mouse
EBs and to those published in the literature from expres-
sion profiling [29-31,44] or large-scale ChIP experiments
[34]. The limited overlap in identified genes with up or
downregulated expression between all these different lists
cannot be easily explained, but could have a number of
different reasons. The tissues, or cell lines studied and spe-
cific mutations varied between the studies. Human as well
as mouse samples were analyzed and they originated from
different stages of the disease process. More likely reasons
may be that overall expression differences between
mutant and wild-type MeCP2 RNA samples are subtle but
affect a large number of genes. An alternate hypothesis is
that MeCP2 primarily regulates expression of a limited
number of genes in very specific cells or in a transient
manner. Such changes would be difficult to detect with
the strategies used in any of these expression profiling
studies.
One of the genes identified by our comparative analysis
was SPOCK1. Its mouse homologue encodes Spock1/tes-
tican, a Ca(2+)-binding proteoglycan predominantly
located in the extracellular matrix. Although its function is
incompletely understood, Spock1/testican contains six
functional domains, several of which have a protease-
inhibitor function [57]. There is an N-terminal hydropho-
bic signal sequence for secretion of the protein in the
extracellular matrix, a cysteine-rich region, a Kazal-like
homology domain with a putative seine-protease inhibi-
tor role, comprised in several regions of homology to
SPARC/osteonectin, two calcium-binding EF hand motifs,
and a C-terminal domain with homology to thyrotropin
cysteine protease inhibitors (CVCW or thyorglobulin-like
domain) that has been shown to inhibit the lysosomal
cysteine protease cathepsin-L [58]. Spock1  is highly
enriched in brain and is associated with the postsynapticBMC Medical Genetics 2006, 7:61 http://www.biomedcentral.com/1471-2350/7/61
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region of a subpopulation of pyramidal neurons in the
CA3 area of the hippocampus [54]. It is also found in the
choroid plexus and is highly enriched in the central nerv-
ous system (CNS) during neuronal proliferation and
migration [52]. It affects neuronal attachment and neurite
outgrowth likely through a modulation of the extracellu-
lar matrix [53]. Quantitative RT-PCR experiments on the
clonal lymphocyte cultures showed only a trend for
downregulation. Quantitative RT-PCR experiments on
brain regions of Mecp2 mutant mice also did not show
consistent changes in expression. This suggests that
SPOCK1 is not a direct target of MeCP2 and its downreg-
ulation in the microarray experiment might have been a
false positive finding.
Conclusion
To find new putative MeCP2 targets, we performed expres-
sion profiling on clonal lymphocyte cultures from RTT
patients with two different MECP2 mutations and com-
pared the gene expression profiles to those of other
screens for MeCP2 targets. No statistically significant dif-
ferences in expression were found upon stringent analysis
of the data. A putative downregulated MeCP2-target gene,
SPOCK1, did not have altered expression in brain regions
in a mouse model of Rett syndrome.
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